Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Income from Continuing Operations (2021 - 2026)

MoonLake Immunotherapeutics' Income from Continuing Operations history spans 6 years, with the latest figure at 69707000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 71.87% to 69707000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 259470000.0 through Mar 2026, down 75.52% year-over-year, with the annual reading at 230321000.0 for FY2025, 89.96% down from the prior year.
  • Income from Continuing Operations came in at 69707000.0 for Q1 2026, down from 63018000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 7887273.0 in Q4 2023 to a low of 70694000.0 in Q3 2025.
  • The 5-year median for Income from Continuing Operations is 17416329.0 (2022), against an average of 31168061.71.
  • The largest YoY upside for Income from Continuing Operations was 69.3% in 2022 against a maximum downside of 20715.22% in 2022.
  • MoonLake Immunotherapeutics' Income from Continuing Operations stood at 16467930.0 in 2022, then soared by 52.11% to 7887273.0 in 2023, then tumbled by 488.23% to 46395000.0 in 2024, then crashed by 35.83% to 63018000.0 in 2025, then fell by 10.61% to 69707000.0 in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Income from Continuing Operations are 69707000.0 (Q1 2026), 63018000.0 (Q4 2025), and 70694000.0 (Q3 2025).